AGY Stock Overview A commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Allergy Therapeutics plc Competitors Price History & Performance
Summary of share price highs, lows and changes for Allergy Therapeutics Historical stock prices Current Share Price UK£0.075 52 Week High UK£0.08 52 Week Low UK£0.018 Beta 1.34 1 Month Change 21.61% 3 Month Change 50.80% 1 Year Change n/a 3 Year Change -73.31% 5 Year Change -33.57% Change since IPO -89.88%
Recent News & Updates See more updates
Less than half of directors are independent Nov 28
Allergy Therapeutics plc Submits Marketing Authorisation Application for Grass MATA MPL Nov 26
Allergy Therapeutics plc, Annual General Meeting, Dec 16, 2024 Nov 22
Allergy Therapeutics plc (LON:AGY) Soars 27% But It's A Story Of Risk Vs Reward Nov 09
Full year 2024 earnings: EPS exceeds analyst expectations Nov 07
New minor risk - Financial data availability Oct 13
Not Many Are Piling Into Allergy Therapeutics plc (LON:AGY) Just Yet Sep 12
New major risk - Share price stability Aug 14
Allergy Therapeutics plc Provides Revenue Guidance for the Second Half and Year Ended 30 June 2024 Jul 23
Allergy Therapeutics plc Appoints David Ball as Non- Executive Director and Chair of the Board's Audit and Risk Committee Jun 27
Allergy Therapeutics plc's (LON:AGY) 28% Share Price Surge Not Quite Adding Up May 21
Allergy Therapeutics plc Provides Further Details from Positive Top Line Results from G306 Phase III Field Study G306 to Evaluate the Efficacy and Safety of Grass MATA MPL May 08
Less than half of directors are independent Apr 10
Allergy Therapeutics Announces Resignation of Mary Tavener as Non-Executive Director Apr 03
Allergy Therapeutics plc Provides Sales Guidance for the Second Half and Full Year Ending on 30 June 2024 Mar 29
First half 2024 earnings released: UK£0.006 loss per share (vs UK£0.013 loss in 1H 2023) Mar 29
New minor risk - Financial data availability Mar 17
Allergy Therapeutics plc Announces Appointment of Shaun Furlong to Board of Directors Mar 12
Allergy Therapeutics plc, Annual General Meeting, Mar 08, 2024 Feb 10
Allergy Therapeutics plc (LON:AGY) Surges 28% Yet Its Low P/S Is No Reason For Excitement Dec 18
Allergy Therapeutics plc Provides an Update on the Data Analysis of Its Pivotal G306 Phase III Trial of Grass MATA MPL Dec 13
Allergy Therapeutics plc Announces Interim Top Line Results from its Pivotal G306 Phase III Trial of Grass MATA MPL Nov 14
New major risk - Revenue and earnings growth Oct 31 Allergy Therapeutics plc has completed a Follow-on Equity Offering in the amount of £6.891025 million. Oct 14
New major risk - Shareholder dilution Oct 13
Full year 2023 earnings: EPS and revenues miss analyst expectations Sep 28
Allergy Therapeutics plc Announces the Completion of Dosing of Healthy Volunteers in the First Two Cohorts in the Phase I Protect Trial of Its Novel Virus-Like Particle (Vlp)-Based Peanut Allergy Vaccine Candidate Sep 26
Allergy Therapeutics plc Announces Executive Changes Jul 11
First half 2023 earnings: EPS misses analyst expectations Jun 20
Allergy Therapeutics plc Provides Sales Guidance for the Second Half Year to 30 June 2023 and Full Year to 30 June 2024 Jun 20
Less than half of directors are independent Jun 19
Allergy Therapeutics plc Provides Revenue Guidance for the Six Months Ended 31 December 2022 Jan 20
Allergy Therapeutics plc, Annual General Meeting, Feb 07, 2023 Jan 14
Allergy Therapeutics Announces Resignation of Scott Leinenweber as Non-Executive Director Dec 28
Allergy Therapeutics Announces Key Updates on Grass MATA MPL and VLP Peanut Clinical Programmes Dec 09
Allergy Therapeutics plc Announces Board Appointments Dec 07
Allergy Therapeutics plc Appoints Martin Hopcroft as Interim CFO Nov 21 Allergy Therapeutics plc Resumes UK Manufacturing Production Allergy Therapeutics plc announced that it has received £17 million in funding from Southern Fox Investments Limited Oct 19
Consensus forecasts updated Oct 06 Allergy Therapeutics plc announced that it expects to receive £10 million in funding from Southern Fox Investments Ltd. and other investor Oct 01
Full year 2022 earnings: EPS and revenues miss analyst expectations Sep 30
Allergy Therapeutics plc, Annual General Meeting, Oct 17, 2022 Sep 30
Price target increased to UK£0.67 Jul 27 Allergy Therapeutics plc Provides Revenue Guidance for the Year Ended 30 June 2022 Allergy Therapeutics plc Announces Resignation of Nick Wykeman to Its Board Director, Effective from November 30, 2022
Price target increased to UK£0.59 Apr 27
Less than half of directors are independent Apr 27
Allergy Therapeutics Shares Data at WAO-BSACI Apr 26
First half 2022 earnings: EPS exceeds analyst expectations Mar 05
Allergy Therapeutics plc Announces the Presentation of Positive New Data from Its Two Lead Immunotherapy Programmes At the 2022 American Academy of Allergy Asthma and Immunology Annual Meeting Held in Phoenix, Arizona Mar 03
FDA Clears Allergy Therapeutics Investigational New Drug Application for Its Novel Virus-Like Particle (VLP )-Based Peanut Allergy Vaccine Candidate Jan 26
Allergy Therapeutics plc Provides Revenue Guidance for the Six Months Ended December 31, 2021 Jan 13
Senior Independent Director Stephen Smith has left the company Nov 29
Senior Independent Director Stephen Smith has left the company Nov 29
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 26
Senior Independent Director Stephen Smith has left the company Nov 26
Senior Independent Director Stephen Smith has left the company Nov 26
Senior Independent Director Stephen Smith has left the company Nov 26
Senior Independent Director Stephen Smith has left the company Nov 26
Senior Independent Director Stephen Smith has left the company Nov 26
Senior Independent Director Stephen Smith has left the company Nov 26
Senior Independent Director Stephen Smith has left the company Nov 26 Shareholder Returns AGY GB Pharmaceuticals GB Market 7D 1.9% -1.3% -0.9% 1Y n/a -5.0% 5.2%
See full shareholder returns
Return vs Market: Insufficient data to determine how AGY performed against the UK Market .
Price Volatility Is AGY's price volatile compared to industry and market? AGY volatility AGY Average Weekly Movement 8.4% Pharmaceuticals Industry Average Movement 7.2% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.7% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: AGY's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: AGY's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders. The company sells injectable and sublingual allergen-specific immunotherapies; and offers treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus.
Show more Allergy Therapeutics plc Fundamentals Summary How do Allergy Therapeutics's earnings and revenue compare to its market cap? AGY fundamental statistics Market cap UK£360.13m Earnings (TTM ) -UK£40.22m Revenue (TTM ) UK£55.20m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) AGY income statement (TTM ) Revenue UK£55.20m Cost of Revenue UK£25.46m Gross Profit UK£29.74m Other Expenses UK£69.95m Earnings -UK£40.22m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.0084 Gross Margin 53.87% Net Profit Margin -72.86% Debt/Equity Ratio 622.8%
How did AGY perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/14 05:20 End of Day Share Price 2025/01/14 00:00 Earnings 2024/06/30 Annual Earnings 2024/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Allergy Therapeutics plc is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Adam McCarter Cavendish Gary Waanders Nomura Code Securities Limited Paul Cuddon Numis Securities Ltd.
Show 4 more analysts 
